What is Zacks Research's Estimate for WST FY2026 Earnings?

West Pharmaceutical Services logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research raised its FY2026 EPS estimate for West Pharmaceutical Services to $9.41 from $8.88, close to the $9.45 consensus, while maintaining a “Hold” rating.
  • West reported quarterly EPS of $2.66, beating the $2.20 analyst consensus, and revenue of $874.5 million exceeded expectations and grew 8.7% year over year.
  • Analyst sentiment overall is more positive: 13 analysts rate the stock “Buy” and one rates it “Hold,” for a MarketBeat consensus of “Moderate Buy” and an average price target of $424.67.
  • MarketBeat previews top five stocks to own in December.

West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) - Stock analysts at Zacks Research upped their FY2026 earnings per share (EPS) estimates for West Pharmaceutical Services in a research report issued on Thursday, November 19th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings of $9.41 per share for the year, up from their previous estimate of $8.88. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for West Pharmaceutical Services' current full-year earnings is $9.45 per share. Zacks Research also issued estimates for West Pharmaceutical Services' Q4 2026 earnings at $2.25 EPS, Q1 2027 earnings at $2.29 EPS, Q2 2027 earnings at $2.54 EPS, Q3 2027 earnings at $2.64 EPS, Q4 2027 earnings at $2.67 EPS, Q1 2028 earnings at $2.61 EPS, Q2 2028 earnings at $3.02 EPS, Q3 2028 earnings at $2.82 EPS and FY2028 earnings at $11.46 EPS.

Other equities research analysts have also issued reports about the stock. Weiss Ratings upgraded shares of West Pharmaceutical Services from a "hold (c+)" rating to a "buy (b-)" rating in a report on Monday, November 2nd. UBS Group increased their target price on shares of West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a "buy" rating in a report on Wednesday, September 9th. Morgan Stanley raised West Pharmaceutical Services from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $365.00 to $400.00 in a research report on Tuesday, September 22nd. Citigroup boosted their price objective on shares of West Pharmaceutical Services from $412.00 to $494.00 and gave the company a "buy" rating in a research report on Friday, October 30th. Finally, TD Cowen upped their target price on West Pharmaceutical Services from $420.00 to $500.00 and gave the stock a "buy" rating in a report on Friday, October 30th. Thirteen investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, West Pharmaceutical Services presently has an average rating of "Moderate Buy" and an average price target of $424.67.

Get Our Latest Stock Analysis on WST

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $397.16 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.10 and a current ratio of 2.82. West Pharmaceutical Services has a fifty-two week low of $223.83 and a fifty-two week high of $438.27. The company has a market capitalization of $27.67 billion, a P/E ratio of 44.57, a PEG ratio of 2.46 and a beta of 1.13. The stock has a 50 day moving average price of $385.77 and a two-hundred day moving average price of $324.32.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, beating analysts' consensus estimates of $2.20 by $0.46. West Pharmaceutical Services had a net margin of 18.81% and a return on equity of 21.78%. The business had revenue of $874.50 million for the quarter, compared to analysts' expectations of $827.12 million. During the same period last year, the business earned $1.96 earnings per share. The business's quarterly revenue was up 8.7% on a year-over-year basis.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in WST. Avalon Trust Co purchased a new stake in West Pharmaceutical Services in the 2nd quarter worth approximately $28,000. Addison Advisors LLC bought a new position in West Pharmaceutical Services in the 2nd quarter worth $28,000. Virtus Advisers LLC bought a new stake in West Pharmaceutical Services during the third quarter valued at about $37,000. Fulcrum Asset Management LLP raised its holdings in West Pharmaceutical Services by 259.4% during the third quarter. Fulcrum Asset Management LLP now owns 115 shares of the medical instruments supplier's stock valued at $43,000 after acquiring an additional 83 shares during the period. Finally, Raiffeisen Bank International AG boosted its stake in shares of West Pharmaceutical Services by 95.6% in the second quarter. Raiffeisen Bank International AG now owns 133 shares of the medical instruments supplier's stock worth $47,000 after acquiring an additional 65 shares during the period. 93.90% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at West Pharmaceutical Services

In related news, VP Annette Favorite sold 2,524 shares of the business's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $365.00, for a total transaction of $921,260.00. Following the completion of the sale, the vice president directly owned 21,818 shares in the company, valued at approximately $7,963,570. The trade was a 10.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 15,659 shares of company stock worth $5,443,749 in the last three months. Insiders own 0.60% of the company's stock.

West Pharmaceutical Services Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 18th. Stockholders of record on Wednesday, November 11th were paid a $0.26 dividend. This is a boost from West Pharmaceutical Services's previous quarterly dividend of $0.22. The ex-dividend date was Tuesday, November 10th. This represents a $1.04 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services's dividend payout ratio (DPR) is currently 11.67%.

West Pharmaceutical Services News Roundup

Here's some of the latest news about WST:

  • Positive Sentiment: Zacks Research raised its earnings estimates across several periods. Its FY2026 EPS forecast increased to $9.41 from $8.88, and its FY2028 forecast rose to $11.46 from $10.74. The higher projections suggest improved expectations for future earnings; the FY2026 estimate is also close to the $9.45 consensus cited in the reports. West Pharmaceutical Services coverage
  • Positive Sentiment: A recent Zacks article cited strong demand for high-value products, expanding biologics exposure and regulatory upgrades as growth supports, while acknowledging near-term headwinds. Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
  • Neutral Sentiment: Despite raising its estimates, Zacks Research maintained a “Hold” rating. The revisions are encouraging but represent one research firm’s forecasts, not a broad upgrade in analyst recommendations. West Pharmaceutical Services analyst coverage

About West Pharmaceutical Services

(Get Free Report)

West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.

Recommended Stories

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in West Pharmaceutical Services Right Now?

Before you consider West Pharmaceutical Services, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.

While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines